SAN DIEGO, March 2, 2011 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed an agreement with Portola Pharmaceuticals, Inc. to develop and supply the VerifyNow System and VerifyNowTests for use in clinical trials.
The VerifyNow System is widely used by practicing physicians to assess patients' platelet response to various antiplatelet therapies already available on the market, such as aspirin, P2Y12 inhibitors (e.g. Plavix® and Effient®)and GP IIb/IIIa inhibitors. The VerifyNow System is also a frequently used tool of clinical researchers to measure the antiplatelet effect of drugs in development. By incorporating the VerifyNow System in pharmaceutical clinical trials, data are generated to support the integration of platelet reactivity testing in the patient care pathway as new agents are introduced to the market.
"With the signing of this agreement, Accumetrics is solidifying its role as a premier partner of pharmaceutical companies in the development and validation of new and emerging antiplatelet drugs," said Timothy I. Still, President and CEO of Accumetrics. "With the trend towards individualized and targeted approaches to treating patients, the VerifyNow System plays an important role at both the commercial and development ends of the spectrum."
The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.
Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics' VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company.
SOURCE Accumetrics, Inc.